Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48 + Envafolimab Neoadjuvant Therapy in HER2 Over-Expressing Muscle-Invasive Bladder Cancer
ChiCTR2300077763Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and envafolimab in bladder cancer and transitional cell carcinoma of the bladder (TCC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Pathological complete response rate (pCR). Planned start Nov 2023; status: not yet recruiting.
02
Drugs
disitamab vedotinenvafolimab
03
Conditions
bladder cancertransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2300077763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077763.